Supplementary Data1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Jennifer Wiggins; Qiao Zhang; Yian Zhang; Fatemeh Vand-Rajabpour; Douglas Hanniford; Linchen He; Yuting Lu; Jessica Kenney; Keimya Sadeghi; Diana Argibay; Irene Orlow; Klaus J. Busam; Cecilia Lezcano; Tim K. Lee; Li Luo; Ivan Gorlov; Christopher I. Amos; Marc S. Ernstoff; Venkatraman Seshan; Anne Ε. Cust; James S. Wilmott; Richard A Scolyer; Graham J. Mann; Allison Reiner; Caroline E. Kostrzewa; Eduardo Nagore; Pauline Funchain; Jennifer S. Ko; Sharon N. Edmiston; Kathleen Conway; Paul B. Googe; David W. Ollila; Jeffrey E. Lee; Judy R. Rees; Cheryl L. Thompson; Meg R. Gerstenblith; Marcus Bosenberg; Bonnie E. Gould Rothberg; Iman Osman; Yvonne M. Saenger; Adam Z. Reynolds; Tawny W. Boyce; Sheri L. Holmen; Shaofeng Yan; Elise K. Brunsgaard; Paul N. Bogner; Pei Fen Kuan; Nancy E. Thomas; Colin B. Begg; Ronglai Shen; Marianne Berwick; Yongzhao Shao; David Polsky; Eva Hernando

doi:10.1158/1078-0432.30883312

Article2025

Supplementary Figures1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Jennifer Wiggins, Qiao Zhang, Yian Zhang, Fatemeh Vand-Rajabpour, Douglas Hanniford, Linchen He, Yuting Lu, Jessica Kenney, Keimya Sadeghi, Diana Argibay, Irene Orlow, Klaus J. Busam, Cecilia Lezcano, Tim K. Lee, Li Luo, Ivan Gorlov, Christopher I. Amos, Marc S. Ernstoff, Venkatraman Seshan, Anne Ε. Cust, James S. Wilmott, Richard A Scolyer, Graham J. Mann, Allison Reiner, Caroline E. Kostrzewa, Eduardo Nagore, Pauline Funchain, Jennifer S. Ko, Sharon N. Edmiston, Kathleen Conway, Paul B. Googe, David W. Ollila, Jeffrey E. Lee, Judy R. Rees, Cheryl L. Thompson, Meg R. Gerstenblith, Marcus Bosenberg, Bonnie E. Gould Rothberg, Iman Osman, Yvonne M. Saenger, Adam Z. Reynolds, Tawny W. Boyce, Sheri L. Holmen, Shaofeng Yan, Elise K. Brunsgaard, Paul N. Bogner, Pei Fen Kuan, Nancy E. Thomas, Colin B. Begg, Ronglai Shen, Marianne Berwick, Yongzhao Shao, David Polsky, Eva Hernando

Article2025

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Jennifer Wiggins, Qiao Zhang, Yian Zhang, Fatemeh Vand-Rajabpour, Douglas Hanniford, Linchen He, Yuting Lu, Jessica Kenney, Keimya Sadeghi, Diana Argibay, Irene Orlow, Klaus J. Busam, Cecilia Lezcano, Tim K. Lee, Li Luo, Ivan Gorlov, Christopher I. Amos, Marc S. Ernstoff, Venkatraman Seshan, Anne Ε. Cust, James S. Wilmott, Richard A Scolyer, Graham J. Mann, Allison Reiner,

Preprint2023

Supplementary Data from Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma

Inês Pires da Silva, Kevin Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham J. Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard F. Kefford, Helen Rizos, Richard A Scolyer, Jean Yang, Georgina V. Long, Alexander M. Menzies

Preprint2023

Supplementary Data from Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma

Inês Pires da Silva, Kevin Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham J. Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard F. Kefford, Helen Rizos, Richard A Scolyer, Jean Yang, Georgina V. Long, Alexander M. Menzies

Dataset

Supplementary Tables from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

Greg Kelly, Fares Al‐Ejeh, Robert McCuaig, Francesco Casciello, Nabilah Ahmad Kamal, Blake Ferguson, Antonia L. Pritchard, Sayed Ali, Ines P. Silva, James S. Wilmott, Georgina V. Long, Richard A Scolyer, Sudha Rao, Nicholas K. Hayward, Frank Gannon, Jason S. Lee

Supplementary Data1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Abstract

Discussion(0)

Related publications

Supplementary Figures1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Supplementary Data from Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma

Supplementary Data from Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma

Supplementary Tables from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

Supplementary Data1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Abstract

Discussion(0)

Related publications

Supplementary Figures1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

Supplementary Data from Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K &lt;i&gt;BRAF&lt;/i&gt;-Mutant Melanoma

Supplementary Data from Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K &lt;i&gt;BRAF&lt;/i&gt;-Mutant Melanoma

Supplementary Tables from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

Supplementary Data from Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma

Supplementary Data from Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma